Hansoh Pharmaceutical’s HS-20093 Granted Breakthrough Therapy Designation by NMPA for Metastatic Castration-Resistant Prostate Cancer 1
Hansoh Pharmaceutical Granted Breakthrough Therapy Designati...
Sign in to continue:
Hansoh Pharmaceutical Granted Breakthrough Therapy Designati...
Milan Station Holdings Limited 2025 Annual Results: Key High...
Suxin Joyful Life Services: Proposed Disposal of Property vi...
Hansoh Pharmaceutical Group: Clinical Trial Approvals for HS...
3SBio Inc. Annual Report 2025: Key Highlights and Investor I...
Trigiant Group Limited Reports Strong Q1 2026 Results and Ex...
Hansoh Pharmaceutical Announces Novation and Transfer of Ost...
Hongcheng Environmental Technology Company Limited 2025 Annu...
1. Financial Performance Overview Revenue: RMB 5,518.5 ...
China Weaving Materials Holdings Limited - 2025 Annual Repor...